About Celldex
About Celldex

Legal Disclaimer | Site Map | Contact
© 2007 CuraGen Corporation


Print Print page | Email Email page

CuraGen Corporation (NASDAQ: CRGN) is a clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. Strategic alliances forged by CuraGen have resulted in a pipeline of potential therapeutics that is being advanced by the Company's experienced team. CuraGen is currently conducting clinical trials with CR011-vcMMAE, an antibody-drug conjugate being developed for the treatment of melanoma, breast cancer and brain tumors. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its therapeutics toward the market and addressing the unmet medical needs of cancer patients.

Annual Meeting and Proxy


Recent News

October 1, 2009
Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation

September 30, 2009
Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation

July 31, 2009
CuraGen Reports Second Quarter 2009 Financial Results

more »

Events

June 3, 2009
CuraGen to discuss presention of CR011-vcMMAE Data at ASCO

May 29, 2009
Conference Call to Discuss CuraGen Acquisition

more »

Shareholder Tools
Stock Quote

Quotes delayed at least 20 minutes.
Information provided by eSignal.